

# Practical Talks for Family Docs

June 20, 2023

1



### Faculty/Presenter Disclosure

#### Faculty: Victor Ng

- Paid Employee of the CFPC
- Assistant Dean and Associate Professor, Schulich School of Medicine and Dentistry



# **Short Snappers for Pride Month:**

# Caring for 2SLGBTQ+ patients in primary care

Drs. Paul Fritsch, Edward Kucharski and Thea Weisdorf

3



### Faculty/Presenter Disclosure

#### Faculty: Paul Fritsch

- Relationships with financial sponsors: none
- GoFreddie (2019-2021): physician prescribing HIV PrEP through virtual platform; received no money, operated through provincial fee-forservice billing

#### Faculty: Edward Kucharski


- Relationship with financial sponsors: Casey House Hospital, Chief Medical Officer
- Editor of Caring for LGBTQ2S People: A clinical guide second edition for which he receives (very modest) royalties

#### Faculty: Thea Weisdorf

- Relationships with financial sponsors: none
- Will be receiving remuneration from the SMHAFHT's Points system for academic productivity
- Member of advisory board for Ontario Breast Screening Program

All three speakers will receive a stipend from the CFPC for this presentation.

Δ



Affirming approaches

Thea Weisdorf, MD CCFP FCFP (she/her)




7



# Transgender and Gender Diverse People

- TGD is broad term to describe individuals whose gender identities and expressions differ from the gender attributed to the sex assigned at birth
- Estimates worldwide range from 0.6% to 3%¹
- Canadian census 2021: 0.3% Canadians 15 years of age and older identify as Transgender or Non Binary<sup>2</sup>
  - 1. Coleman E, Radix AE, Bouman WP, et al. Standards of care for the health of transgender and gender diverse people, version 8. Int J Transgend Health. 2022;23(suppl 1):S1-S259. doi:10.1080/26895269.2022.2100644
  - 2. https://www.statcan.gc.ca/en/census/census-engagement/community-supporter/sex-birth-gender



Which of the following is the Transgender Flag?

A.

B.

C.

D.

\_



# SOC-8 Clinical Guidelines for Transgender and Gender Diverse People (TGD)<sup>1</sup>

- Released September 2022
- Developed and funded by World Professional Association for Transgender Health (WPATH)
- Replaced the 2012 version
- Major recommendations addressing Primary Care, Assessment of TGD persons, Mental health, Medication and Surgery


1. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8, E., Coleman, https://www.tandfonline.com/doi/full/10.1080/26895269.2022.2100644

11





# Barriers to accessing medical care

- 2019 systemic review showed 27% (19%-40%) TGD persons had been denied care by a health professional3
- 2018 study of primary care clinicians found 85% willing to provide care for TGD persons but 52% were unfamiliar with guidelines4
- TGD persons self reported mean poor mental health of 14.8 days/mo compared with 6.0 for cisgender participants<sup>5</sup>
- Scheim Al, Baker KE, Restar AJ, Sell RL. Health and health care among transgender adults in the United States. Annu Rev Public Health. 2022;43: 503-523. doi:10.1146/annurev-publihealth-052620-100313
  Shires DA, Stroumsa D, Jaffee KD, Woodford MR. Primary care clinicians' willingness to care for transgender patients. Ann Fam Med. 2018;16(6): 555-558. doi:10.1370/afm.2298
  Feldman JL, Luhur WE, Herman JL, Poteat T, Meyer IH. Health and health care access in the US transgender population health (TransPop) survey. Andrology. 2021;9(6):1707-1718. doi:10.1111/andr. 13052



Language: Description of Body Parts/Clothing - It Matters **GENDERED TERMS** LESS GENDERED TERMS These terms may be uncomfortable or distressing for trans men to hear. Try your best to use neutral and inclusive terminology to avoid patient discomfort. If you are unsure, ask what terms your client prefers. Breasts Chest Vulva External Pelvic Area Vagina Genital Opening, Frontal Pelvic Opening, Internal Cana Uterus, Ovaries Internal Organs Pap smear Cancer screening Bra, Panties Underwear Period, Menstruation Bleeding







Which of the following are things you can do to promote a welcoming environment for your TGD patients?

- a) Ensure office staff are familiar with using correct names, pronouns
- b) Put posters in waiting areas, offices promoting gender-affirming care
- c) Provide gender neutral washrooms in your clinic space
- d) If your EMR only allows name on Health Card which is not the name your patient identifies with, ensure visible area on EMR to write authentic name
- e) All of the above

17




#### Resources:

- Sherbourne Health website for 2S:LGBTQ Health
   https://sherbourne.on.ca/primary-and-family-health-care/2slgbtg-health/
- Guidelines for Gender Affirming Primary Care with Trans and Non Binary Patients. 2019: www.rainbowhealthontario.ca/product/4th-edition-sherbournes-guidelines-for-gender-affirming-primary-care-with-trans-and-non-binary-patients/
- Standards of Care for the Health of Transgender and Gender Diverse People, Version 8, E. Coleman et al.

https://www.tandfonline.com/doi/full/10.1080/26895269.2022.2100644

 Gender Affirming Care for Trans, Two-Spirit and Gender Diverse Patients in BC: Primary Care Toolkit. 2023

http://www.phsa.ca/transcarebc/Documents/HealthProf/Primary-Care-Toolkit.pdf



But, before we get started:

Communication
Intersectionality
Ever evolving language
Double-edge sword = less access
Let the tissue/organ system guide you!

19

Anal sex is a risk factor for HPV-related anal cancer MSM high prevalence of HPV-related anal & oral cancers MSM: HIV+ MSM have an even higher risk Cancer Increasing incidence of anal cancer seen due to treatment of HIV Prevention, No widely accepted screening recommendations maybe but some specialists recommend screening for all HIV+ MSM with cytology and DARE screening? **ANCHOR STUDY!** Don't forget HPV vaccine (and others!)

WSW:
Cancer
Screening
(and
Prevention?)

- · Cervical cancer screening
- Breast Cancer Screening
- Other risk factors smoking, obesity

21

# Screening for Trans and Nonbinary People

- Trans and nonbinary people face unique barriers when accessing cancer screening including:
  - Healthcare providers may not understand their needs<sup>1</sup>
  - Absence of trans-specific cancer screening guidelines
  - System-level data infrastructure limitations
- These barriers can contribute to trans people being less up-todate with breast cancer and cervical screening than cisgender women<sup>2-4</sup>

23

# Breast/Chest Screening for Trans and Nonbinary people

#### **Average Risk**

- Screen average risk transfeminine and nonbinary people with a history of 5 or more consecutive years of cross-sex hormone (CSH) use AND between the ages of 50 and 74 with mammography every 2 years
- Screen eligible average risk
   transmasculine and nonbinary people
   between the ages of 50 and 74 with
   mammography every 2 years


# Some points on Breast Cancer in Transfeminine women


- There have only been 21 recorded cases of breast cancer since 1968!
- Factors that may reduce the risk less lifetime or cyclical hormone exposure, little or no progesterone exposure.
- Dutch and US Retrospective Studies

25

# Cervical Screening

- Screen average risk transmasculine and nonbinary people with a cervix between the ages of 25\* and 69 with cytology every 3 years if sexually active
- Offer screening to eligible transmasculine and nonbinary people who are due for screening before removal of the cervix
- If appropriate for **transfeminine and nonbinary people**, clinicians should consider visual exam and/or vaginal cytology of the neovagina (in practice, this is seldom done)







# HIV PrEP: Approach and Clinical Pearls

Paul Fritsch, MD CCFP

29

## References

GUIDANCE FOR THE USE OF PRE-EXPOSURE PROPHYLAXIS (PrEP) FOR THE PREVENTION OF HIV ACQUISITION IN BRITISH COLUMBIA

(August 2019 - last updated June 2020). Retrieved June 5, 2023 from:

https://www.bccfe.ca/publications/centre-documents/guidance-for-the-use-pre-exposure-prophylaxis-prep-prevention-hiv-acquisition

\*\*BC Centre for Excellence Resources\*\*

# What is PrEP?

2 HIV meds (NRTIs) in single pill:

1. Tenofovir disoproxil fumarate / emtricitabine (TDF/FTC)  $_{\it Truvada^{\it TM}}$ 

OR

2. Tenofovir alafenamide / emetrictabine (TAF/FTC)  ${\it Descovy}^{\rm TM}$ 

31

# How is PrEP taken?

#### **Daily PrEP**

• Taken once daily to prevent HIV infection at any time

#### **On-Demand PrEP** (off-label)

- 2 pills taken 2-24h before sexual activity, then 1 pill 24h later, and another pill 24h after that
  - "2-1-1 method"
  - Only for anal sex
  - CANNOT be used if HBV co-infected
  - ∗\*Only approved for TDF/FTC version of PrEP (*Truvada*™)\*\*

# Who is appropriate for PrEP?

- Cis and transgender MSM and TGW with:
  - Rectal bacterial STI or syphilis in last year
  - · Repeated PEP use
  - HIRI score >=10
  - HIV positive partner with detectable VL
  - · Heterosexuals with partner with detectable VL
  - · Sex workers should be assessed
  - People who inject drugs should be assessed

33

#### HIRI Score

Question	Question	Response	Score
Number			
1	How old are you today (years)	<18 years	0
		18-28	8
		29-40	5
		41-48	2
		≥49	0
2	How many men have you had sex	>10	7
	with in the last 6 months?	6-10	4
		0-5	0
3	How many of your male sex	>1 positive partner	8
	partners were HIV positive?	1 positive partner	4
		<1 positive partner	0
4	In the last 6 months, how many	≥ 1 time	10
	times did you have receptive anal	0 times	0
	sex (you were the bottom) with a		
	man without a condom?		
5	In the last 6 months, how many	5 or more times	6
	times did you have insertive anal sex	0-4 times	0
	(you were the top) with a man who		
	was HIV positive?		
6	In the last 6 months, have use used	Yes	5
	methamphetamines such as crystal	No	0
	or speed?		
7	In the last 6 months, have you used	Yes	3
	poppers (amyl nitrate)?	No	0
		Total	

https://www.albertahealthservices.ca/ assets/info/hp/srh/if-hp-srh-hiv-prepguidelines.pdf

# PrEP side effects

- · Generally well tolerated
- Most commonly reported side effect in studies is:
  - Nausea
  - Other GI side effects (at most for 4 weeks)
- Long term side-effects may include (mainly tenofovir):
  - Kidney injury (reversible)
  - Bone mineral density loss (?clinically significant)

35

# Lab work monitoring timeline

Baseline	30 days	<b>Q90days thereafter</b>
HIV testing	HIV testing	HIV testing
Syphilis serology	Creatinine	Syphilis serology
G+C (various sites)		G+C (various sites)
HepBsAg, HepBsAb, HepBcAb		Creatinine
Creatinine		
HAV		HCV q6-12months
HCV		
CBC		
Urinalysis / ACR		
+/- Pregnancy test		



Resources from the CFPC

Visit our CFPC Pride webpage
www.cfpc.ca/pride to find:

Podcasts
Webinars
CFPC
PRIDE

CMFC
FIERTÉ

CMFC
FIERTÉ

Interested in joining the 2SLGBTQ+ Health Member Interest Group? Email us at migs@cfpc.ca.